Vertex Pharmaceuticals Incorporated (VRTX)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Vertex Pharmaceuticals Incorporated (“Vertex” or the “Company) (NASDAQ: VRTX). Investors who purchased Vertex securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Vertex and certain of its officers and/or directors have violated federal securities laws.
On May 2, 2022, Vertex issued a press release providing an update on its Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy for people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemia. Specifically, the press release revealed that “the VX-880 Phase 1/2 study has been placed on clinical hold in the U.S. by the Food and Drug Administration (FDA) due to a determination that there is insufficient information to support dose escalation with the product.” On this news, Vertex’s stock price fell $11.26 per share, or 4.12%, to close at $261.96 per share on May 2, 2022.
If you are aware of any facts relating to this investigation or purchased Vertex shares you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.